» Articles » PMID: 26635102

Comparison of 10-day Sequential Therapy with 7-day Standard Triple Therapy for Helicobacter Pylori Eradication in Inactive Peptic Ulcer Disease and the Efficiency of Sequential Therapy in Inactive Peptic Ulcer Disease and Non-ulcer Dyspepsia

Overview
Publisher Biomed Central
Specialty Gastroenterology
Date 2015 Dec 5
PMID 26635102
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Eradication rates of standard triple therapy for Helicobacter pylori infections have decreased in recent years due to a worldwide increase in bacterial resistance. Sequential therapy has the advantage of a two-phase treatment regimen and achieves a superior result for H. pylori eradication in peptic ulcer disease. However, no study has yet compared the efficacy of sequential therapy for H. pylori eradication exclusively in inactive duodenal ulcer (iDU) or non-ulcer dyspepsia (NUD).

Method: We retrospectively recruited 408 patients with endoscopic proven iDU (170 patients) or NUD (238 patients) infected with H. pylori. Patients with iDU were assigned into two groups: iDU triple therapy group, 44 patients treated with 40 mg pantoprazole, 1000 mg amoxicillin and 500 mg clarithromycin, twice daily for 7 days; iDU sequential therapy group, 126 patients treated with 40 mg pantoprazole and 1000 mg amoxicillin, twice daily for the first 5 days, followed by 40 mg pantoprazole, 500 mg clarithromycin and 500 mg tinidazole, twice daily for the next 5 days. All patients with NUD were treated with sequential therapy and assigned as the NUD sequential group. Post-treatment H. pylori status was confirmed by a (13)C-urea breath test.

Result: The eradication rates of intention-to-treat (ITT) and per-protocol (PP) analysis were 77.3 % (95 % CI 64.9-89.7 %) and 85.0 % (95 % CI 73.9-96.1 %) in the iDU triple therapy group and 87.3 % (95 % CI 81.5-93.1 %) and 92.4 % (95 % CI 87.6-97.2 %) in the iDU sequential therapy group. The overall eradication efficacy was superior in the sequential group than in the triple group, both with ITT analysis (83.5 % vs. 77.3 %, P = 0.29) and PP analysis (88.1 % vs. 85.0 %, P = 0.57). Eradication rates for ITT and PP analysis were 81.5 % (95 % CI 76.6-86.4 %) and 85.8 % (95 % CI 83.5-88.2 %) in the NUD sequential therapy group. Eradication rate was statistically better in the iDU sequential therapy group than the NUD sequential therapy group according to per protocol analysis (P = 0.04). Eradication rate was not significantly different between the iDU sequential- and iDU triple therapy groups according to protocol analysis (P = 0.14).

Conclusion: The sequential regimen has a better eradiation rate in the iDU group than in the NUD group. There is no statistically difference between 10-day sequential therapy and 7-day standard triple in iDU group.

Citing Articles

Benign biliary conditions with increased risk of malignant lesions.

Welle C, Khot R, Venkatesh S, Paspulati R, Ganeshan D, Fulcher A Abdom Radiol (NY). 2024; .

PMID: 39433602 DOI: 10.1007/s00261-024-04630-z.


A review on anti-peptic ulcer activities of medicinal plants used in the formulation of and .

Kumadoh D, Archer M, Yeboah G, Kyene M, Boakye-Yiadom M, Adi-Dako O Heliyon. 2021; 7(12):e08465.

PMID: 34917789 PMC: 8645450. DOI: 10.1016/j.heliyon.2021.e08465.


Comparison of 10 and 14 days of triple therapy versus 10 days of sequential therapy for Helicobacter pylori eradication: A prospective randomized study.

Ennkaa A, Shaath N, Salam A, Mohammad R Turk J Gastroenterol. 2018; 29(5):549-554.

PMID: 30260776 PMC: 6284607. DOI: 10.5152/tjg.2018.17707.


Adding Bismuth to Rabeprazole-Based First-Line Triple Therapy Does Not Improve the Eradication of .

Wu M, Wang Y, Liu C, Yu F, Kuo F, Liu M Gastroenterol Res Pract. 2017; 2017:5320180.

PMID: 28791044 PMC: 5534286. DOI: 10.1155/2017/5320180.


The natural history of perforated foregut ulcers after repair by omental patching or primary closure.

Smith D, Roeser M, Naranjo J, Carr J Eur J Trauma Emerg Surg. 2017; 44(2):273-277.

PMID: 28756513 DOI: 10.1007/s00068-017-0825-3.

References
1.
Vaira D, Vakil N . Blood, urine, stool, breath, money, and Helicobacter pylori. Gut. 2001; 48(3):287-9. PMC: 1760150. DOI: 10.1136/gut.48.3.287. View

2.
Bazzoli F, Pozzato P, Zagari M, Fossi S, Ricciardiello L, Nicolini G . Efficacy of lansoprazole in eradicating Helicobacter pylori: a meta-analysis. Helicobacter. 1998; 3(3):195-201. DOI: 10.1046/j.1523-5378.1998.08029.x. View

3.
Gisbert J, Calvet X, OConnor A, Megraud F, OMorain C . Sequential therapy for Helicobacter pylori eradication: a critical review. J Clin Gastroenterol. 2010; 44(5):313-25. DOI: 10.1097/MCG.0b013e3181c8a1a3. View

4.
Hsu P, Lai K, Lo G, Tseng H, Lo C, Chen H . Risk factors for ulcer development in patients with non-ulcer dyspepsia: a prospective two year follow up study of 209 patients. Gut. 2002; 51(1):15-20. PMC: 1773281. DOI: 10.1136/gut.51.1.15. View

5.
Gatta L, Vakil N, Leandro G, Di Mario F, Vaira D . Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. Am J Gastroenterol. 2009; 104(12):3069-79. DOI: 10.1038/ajg.2009.555. View